🔍 Featured Answer: What Is BPC-157 in Simple Terms?
Question: What is BPC-157 and why is it widely researched?
Direct Answer: BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in human gastric juice. It is one of the most extensively studied research peptides for tissue repair and wound healing, with preclinical evidence suggesting it promotes healing in muscle, tendon, ligament, bone, and nervous tissue through multiple regenerative pathways.
Supporting Context: Over 100 preclinical studies — predominantly conducted by Dr. Predrag Sikiric’s group at the University of Zagreb — have documented BPC-157’s effects in rodent models of tissue injury, gastrointestinal damage, and neurological injury. The compound is notable for its multi-tissue healing potential and its remarkable safety profile in animal studies, with no observed toxic dose identified in rodent research.
- BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice protein BPC
- Over 100 published preclinical studies document its healing effects across muscle, tendon, ligament, bone, gut, and nervous system tissue
- Research identifies multiple mechanisms including upregulation of growth factor receptors (VEGFR2, FGFR), nitric oxide production, and angiogenesis promotion
- BPC-157 is notable for oral bioavailability in rodent studies — unique among peptides of its size — though human oral bioavailability has not been confirmed in clinical trials
- No toxic dose has been identified in rodent research; the compound shows an unusually broad safety window in preclinical models
- No large-scale human clinical trials for tissue repair have been completed as of 2025; most evidence is preclinical
- Health coaches and wellness professionals need to understand the distinction between preclinical evidence and established clinical evidence when discussing research peptides with clients
Table of Contents
- What Is BPC-157?
- How BPC-157 Works: Key Mechanisms
- Multi-Tissue Healing Research
- Gastrointestinal Research: The Original Application
- Tendon and Ligament Repair Research
- Muscle Healing and Recovery Research
- Nervous System and Neuroprotection Research
- The Oral Bioavailability Question
- BPC-157 Research Summary Table
- Key Research Numbers
- What Health Coaches and Wellness Professionals Should Know
- Limitations and Research Gaps
- Frequently Asked Questions
- Related Articles
- Related Products
- Related Research Plans
- Scientific References
- Conclusion
What Is BPC-157?
BPC-157 stands for Body Protection Compound 157 — a name reflecting its origins as a sequence isolated from the protective protein found in human gastric juice. The full name of this parent protein is Body Protection Compound (BPC), and BPC-157 is a specific 15-amino-acid subsequence (amino acid sequence: GEPPPGKPADDAGLV) identified by researchers as having the most potent and stable biological activity of multiple candidate sequences tested.
The compound was primarily developed and researched by Professor Predrag Sikiric and colleagues at the University of Zagreb School of Medicine in Croatia, who have published the majority of the approximately 100+ studies on BPC-157 over the past three decades. Their research began with gastrointestinal applications — investigating BPC-157’s cytoprotective effects on the stomach lining — and progressively expanded to encompass virtually every major tissue type, including muscle, tendon, ligament, bone, brain, spinal cord, heart, and peripheral nerves.
BPC-157 is a fully synthetic peptide — meaning it is produced in the laboratory via chemical synthesis rather than being isolated from biological sources. Research-grade BPC-157 is typically supplied as a lyophilised (freeze-dried) white powder, which is stable for extended periods when stored at appropriate temperatures (-20°C before reconstitution). For research use, it is typically reconstituted in bacteriostatic water before administration in experimental settings.
A key characteristic distinguishing BPC-157 from many other research peptides is its reported stability in biological environments. Unlike many peptides that are rapidly degraded by stomach acid and digestive enzymes, BPC-157 shows remarkable stability in gastric conditions — a property consistent with its origin from a protein evolved to exist in the gastric environment. This stability underpins much of the research into its oral bioavailability, which has been documented in rodent studies (though not yet confirmed in human clinical trials).
How BPC-157 Works: Key Mechanisms
BPC-157’s wide-ranging tissue-healing effects are mediated through several parallel mechanisms that researchers have partially characterised in preclinical studies. Understanding these mechanisms helps health professionals and researchers contextualise the compound’s effects across different tissue types and injury models.
The first and most extensively studied mechanism is the upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) — the primary receptor for VEGF, the master regulator of angiogenesis (new blood vessel formation). BPC-157 has been shown to increase VEGFR2 expression and downstream signalling, promoting the growth of new capillaries into damaged tissue. This angiogenic effect is fundamental to tissue repair because adequate vascular supply is a prerequisite for delivering oxygen, nutrients, and growth factors to healing tissue.
The second major mechanism involves the nitric oxide (NO) system. Research demonstrates BPC-157 modulates endothelial nitric oxide synthase (eNOS) activity, influencing local nitric oxide production. NO plays multiple roles in tissue healing: it promotes vasodilation (improving blood flow to injured areas), regulates inflammatory cell recruitment, and stimulates fibroblast proliferation. BPC-157’s effects on the NO system may help explain its anti-inflammatory and tissue repair promoting effects across diverse tissue types.
Third, BPC-157 has been shown to influence the expression and signalling of multiple growth factor receptors beyond VEGFR2, including receptors for EGF (epidermal growth factor), FGF (fibroblast growth factor), and HGF (hepatocyte growth factor). These growth factors collectively regulate cell proliferation, migration, and differentiation across epithelial, mesenchymal, and endothelial cell populations — providing a mechanistic basis for BPC-157’s effects in multiple tissue types simultaneously.
Fourth, in the gastrointestinal system specifically, BPC-157 influences the prostaglandin system and appears to modulate interactions between the enteric nervous system and gastrointestinal immune function, pathways of particular relevance to gut barrier integrity and ulcer healing.
Key Insight: BPC-157’s multi-tissue effectiveness — unusual for a single small peptide — is explained by its targeting of fundamental biological processes (angiogenesis, growth factor signalling, nitric oxide) that are required for tissue repair across ALL tissue types, rather than targeting tissue-specific molecular targets.
Why It Matters: Health coaches researching peptide science for client education should understand that BPC-157 is not a tissue-specific compound. Its mechanisms are foundational to repair biology in general — which is why the research spans from gut healing to tendon repair to neuroprotection. This also means its effects are context-dependent: the same mechanisms produce different visible outcomes in different tissue injury models.
Multi-Tissue Healing Research
The scope of BPC-157’s documented preclinical healing effects is remarkable in its breadth. Research published across peer-reviewed journals — predominantly from the Zagreb group and increasingly from independent research laboratories globally — has examined BPC-157’s effects in rodent models of: gastric ulcers, inflammatory bowel disease, Crohn’s-like intestinal damage, Achilles tendon transection, muscle crush injury, ligament transection, bone fracture, spinal cord injury, peripheral nerve crush, traumatic brain injury, cardiac ischemia, hepatic damage, and corneal wound healing.
In each of these models, BPC-157 has demonstrated statistically significant improvements in healing rates, tissue quality, or functional recovery compared to control groups — a consistency across organ systems that has prompted researchers to describe it as having a “whole-body cytoprotective” mechanism rather than a tissue-specific one.
This multi-tissue profile is of particular professional interest to health coaches and wellness practitioners who work with clients experiencing musculoskeletal recovery challenges, digestive health issues, and age-related connective tissue degradation simultaneously — common comorbidities in the client populations served by functional health professionals.
Gastrointestinal Research: The Original Application
The gastrointestinal research on BPC-157 is the oldest and arguably most robust component of its evidence base, having been published since the early 1990s. Studies in rodent models of gastric ulcers, NSAID-induced gut damage, alcohol-induced gut damage, and inflammatory bowel disease consistently demonstrate that BPC-157 accelerates mucosal healing, preserves gut barrier integrity, and reduces inflammatory damage to the intestinal epithelium.
Of particular relevance to modern wellness practice is research showing BPC-157 counteracts NSAID-induced gut damage — a clinically significant finding given how commonly non-steroidal anti-inflammatory drugs are used by athletes and active individuals for pain management, often at the cost of intestinal permeability and mucosal damage. The gastric origin of BPC-157 (derived from human gastric juice BPC) provides a compelling biological rationale for its gastrointestinal effects — it appears to replicate and amplify the body’s own stomach-protective mechanisms.
Research also documents BPC-157’s effects on gut motility disorders, hepatic damage, and oesophageal lesions, expanding its gastrointestinal research profile beyond simple ulcer models into the broader territory of digestive system integrity — an area of growing interest in functional medicine and integrative health practice.
Tendon and Ligament Repair Research
Tendon and ligament injuries are among the most common musculoskeletal challenges in athletic and active populations, yet they remain among the most difficult to treat effectively due to the poor vascular supply and slow healing kinetics characteristic of dense connective tissue. BPC-157’s documented angiogenic properties — promoting new blood vessel formation into poorly vascularised tissue — provide a compelling research rationale for its application to tendon and ligament healing.
Studies by Sikiric and colleagues using the transected Achilles tendon model in rats have consistently shown that BPC-157-treated animals demonstrate faster tendon continuity restoration, improved tendon tissue organisation (as measured by histological analysis), and superior functional recovery of plantar flexion strength compared to controls. Similar findings have been reported for transected medial collateral ligament, rotator cuff lesions, and quadriceps muscle-to-bone junction injuries.
For health coaches working with clients recovering from sports injuries, orthopaedic surgeries, or chronic tendinopathies, the BPC-157 tendon and ligament research is frequently cited as one of the most practically relevant components of the compound’s preclinical profile — though it is essential to clearly communicate to clients that these are rodent model findings that have not yet been validated in human clinical trials.
Key Insight: Tendons and ligaments heal slowly in part because of their inherently poor blood supply — relatively few blood vessels penetrate their dense collagen matrix. BPC-157’s promotion of VEGFR2-mediated angiogenesis specifically targets this limitation by stimulating new vessel ingrowth into the injury site, potentially addressing the fundamental vascular bottleneck in connective tissue healing.
Why It Matters: This is why BPC-157 research in tendon healing is considered particularly important — it is not merely accelerating a process that would occur anyway, but potentially enabling a level of vascular supply that would not develop without intervention, with mechanistic implications for both speed and quality of tendon tissue regeneration.
Muscle Healing and Recovery Research
Skeletal muscle has considerably better inherent healing capacity than tendon or ligament due to its abundant blood supply and resident satellite cell (muscle stem cell) population. Nevertheless, BPC-157 has been shown to accelerate muscle healing in rodent models of crush injury, toxin-induced muscle damage, and surgical muscle transection — findings that have drawn attention from sports medicine researchers and the performance community.
Research examining BPC-157’s effects on muscle repair has documented accelerated myofibre regeneration, reduced inflammatory infiltration, and improved restoration of muscle architecture and contractile function in treated animals compared to controls. The compound appears to promote satellite cell activation and myoblast differentiation — the cellular processes responsible for new muscle fibre formation — through growth factor receptor modulation and the NO signalling system.
Additionally, BPC-157’s anti-inflammatory effects in muscle tissue may be relevant to the overtraining and excessive inflammatory response scenarios that health coaches frequently observe in clients who overtrain without adequate recovery. Reducing pathological chronic inflammation while preserving the acute inflammatory response needed for adaptation is a nuanced research target — one that BPC-157’s preclinical profile appears to address in animal models.
Nervous System and Neuroprotection Research
Perhaps the most surprising extension of BPC-157’s research portfolio is into the nervous system. Studies in rodent models of spinal cord injury, peripheral nerve crush injury, and traumatic brain injury have documented neuroprotective effects — accelerated functional recovery, reduced secondary damage, and improved histological outcomes — that position BPC-157 as a compound of interest in neurological research.
The mechanism of neuroprotection is less fully characterised than BPC-157’s peripheral tissue healing effects. Proposed mechanisms include nitric oxide modulation (NO plays important roles in neural signalling and neuroprotection), effects on neurotrophic factor expression, and direct cytoprotective effects on neurons exposed to oxidative stress or ischemic conditions. Research has also examined BPC-157’s effects on neurotransmitter systems — including dopaminergic and serotonergic pathways — suggesting potential research applications in psychiatric and mood disorder models.
For health coaches, this neurological research dimension is particularly relevant when working with clients who have experienced concussions, whiplash injuries, or peripheral nerve entrapment syndromes — increasingly recognised areas of concern in contact sports and physically demanding occupations.
The Oral Bioavailability Question
One of the most discussed and controversial aspects of BPC-157 research is its apparent oral bioavailability in rodent studies — a pharmacological property almost unheard of for a peptide of its size. Most peptides are degraded by digestive enzymes in the gastrointestinal tract before reaching systemic circulation, making oral administration generally ineffective. BPC-157’s stability in gastric conditions and its origin from a protein evolved to exist in gastric juice appear to confer unusual resistance to gastrointestinal degradation.
Rodent studies from the Zagreb group have demonstrated that BPC-157 is biologically active when administered orally at doses that produce effects comparable to parenteral (injection) administration in the same animal models. This is a remarkable finding if confirmed — oral bioavailability would dramatically expand the practical research applications and accessibility of the compound.
However, critical caution is warranted: oral bioavailability in rodents does not automatically translate to humans. The gastrointestinal anatomy, enzyme profiles, and first-pass hepatic metabolism of rodents differ substantially from humans in ways that can profoundly affect peptide bioavailability. Human pharmacokinetic studies to confirm oral bioavailability have not been published as of 2025. Health coaches should clearly communicate this limitation to clients who ask about oral vs. injectable BPC-157 research products.
BPC-157 Research Summary Table
| Research Area | Key Finding | Evidence Level | Key Researcher/Reference |
|---|---|---|---|
| Tendon Healing | Accelerated Achilles tendon repair, improved histology | Rodent models | Sikiric et al. (multiple) |
| Gut Protection | Ulcer healing, NSAID damage prevention, IBD improvement | Rodent models, in vitro | Sikiric et al. (multiple) |
| Muscle Repair | Faster myofibre regeneration, reduced inflammatory damage | Rodent models | Sikiric group + independent labs |
| Ligament Healing | Improved MCL repair, bone-tendon junction healing | Rodent models | Sikiric et al. |
| Neuroprotection | Improved recovery after spinal cord, peripheral nerve, TBI injury | Rodent models | Sikiric group |
| Angiogenesis | VEGFR2 upregulation, new vessel formation | In vitro + rodent models | Chang et al., 2011 |
| Oral Bioavailability | Active orally in rodent studies; human data lacking | Rodent models only | Sikiric group |
Key Research Numbers
Statistics Section: BPC-157 in Numbers
- 15 amino acids — Length of the BPC-157 peptide (sequence: GEPPPGKPADDAGLV)
- 100+ — Approximate number of published peer-reviewed studies on BPC-157 (primarily preclinical)
- 30+ years — Duration of BPC-157 research since Sikiric group’s early publications in the early 1990s
- No toxic dose identified — BPC-157 has not produced a lethal or clearly toxic dose in rodent studies (unusually broad safety window for a research compound)
- 2.02 µg/kg — One of the lowest effective doses documented in BPC-157 rodent studies (stomach cytoprotection model)
- 10+ tissue types — Number of distinct tissue types in which BPC-157 has demonstrated healing effects in preclinical research
- 0 large-scale human RCTs — Number of large-scale randomised controlled human clinical trials for tissue repair indications (as of 2025)
- VEGFR2 — The primary growth factor receptor upregulated by BPC-157 that mediates its angiogenic effects
What Health Coaches and Wellness Professionals Should Know
Health coaches and wellness professionals occupy a unique position in the client-researcher-practitioner ecosystem: clients frequently bring questions about research peptides like BPC-157 to wellness consultations, expecting informed guidance from their trusted health professional. Understanding the evidence base — and, equally importantly, its limitations — is essential for responsible and effective client communication.
The most critical distinction to communicate is between preclinical evidence and established clinical evidence. BPC-157’s 100+ preclinical studies in rodent models represent a compelling body of mechanistic and proof-of-concept data, but they do not constitute clinical proof of efficacy or safety in humans. The history of medical research contains many examples of compounds that showed promise in animal models but failed to translate to human benefit — or revealed unforeseen safety concerns — in clinical trials. This is not a reason to dismiss BPC-157 research, but it is an essential epistemic framework for accurate client communication.
Wellness professionals should also be aware that clients in Vietnam who are researching BPC-157 may have access to research-grade products from suppliers like Vietnam Peptides. The distinction between research-grade peptides (intended for scientific investigation) and therapeutic products (which would require regulatory approval and clinical validation) is an important one for client education conversations.
Finally, health coaches should maintain currency with the BPC-157 research literature, which is evolving. Several investigator-initiated clinical studies are underway as of 2025, and the body of evidence is expected to grow significantly in the coming years as interest in this compound continues to expand in the global sports medicine and integrative health communities.
Limitations and Research Gaps
The BPC-157 evidence base carries significant limitations that researchers and health professionals must understand and communicate accurately. The most fundamental is the research concentration: the vast majority of BPC-157 studies come from a single research group (Sikiric et al. at the University of Zagreb), creating a concern about independent replication. While some independent laboratories have begun investigating BPC-157, the evidence base lacks the diversity of research groups that characterises well-established therapeutic compounds.
The complete absence of large-scale, randomised, placebo-controlled human clinical trials for any tissue repair indication is a critical gap. Phase I safety studies in humans are minimal, and Phase II efficacy data is absent. Without this clinical evidence, BPC-157 remains firmly in the research compound category regardless of the compelling preclinical findings.
The mechanism of action, while partially characterised, remains incompletely understood. Multiple mechanistic pathways have been proposed and partially evidenced, but a unified mechanistic model explaining all of BPC-157’s diverse effects has not been established. This mechanistic incompleteness makes it difficult to predict interactions with other compounds, pathological states, or individual biological variability in humans.
Frequently Asked Questions
A: BPC-157 stands for Body Protection Compound 157. It is a 15-amino-acid synthetic peptide derived from a protective protein sequence found naturally in human gastric juice, originally identified and researched extensively by Professor Predrag Sikiric’s group at the University of Zagreb.
A: The amino acid sequence of BPC-157 is derived from a naturally occurring human gastric protein, but the peptide itself is produced through chemical synthesis (solid-phase peptide synthesis) in the laboratory. It is considered “nature-derived but synthetically produced” — similar in concept to many pharmaceutical compounds based on natural molecule templates.
A: Research covers an unusually broad range of tissues including: gastrointestinal mucosa (stomach, intestine, colon), muscle, tendon, ligament, bone, cartilage, liver, heart, kidney, spinal cord, peripheral nerves, brain, cornea, and blood vessels. This multi-tissue research profile is rare for a single peptide and stems from BPC-157’s targeting of fundamental healing mechanisms (angiogenesis, growth factor signalling, nitric oxide) that operate across all tissue types.
A: BPC-157 has not been through large-scale randomised controlled human clinical trials for tissue repair indications as of 2025. There is limited Phase I safety data in humans, but the comprehensive human efficacy and safety evidence that characterises approved pharmaceuticals is absent. All major tissue healing findings are from preclinical (rodent) studies.
A: No. BPC-157 and TB-500 are distinct research compounds with different structures and mechanisms. BPC-157 is a 15-amino-acid peptide derived from gastric juice BPC protein. TB-500 is a synthetic analogue of the C-terminal sequence of Thymosin Beta-4, a 44-amino-acid peptide involved in actin polymerisation regulation and tissue repair. They are sometimes used together in research stacks because their mechanisms of tissue repair are complementary rather than overlapping.
A: BPC-157 is one of the most commonly discussed research peptides in wellness, functional medicine, and sports recovery communities. Health coaches whose clients are athletes, active professionals, or biohackers will increasingly encounter questions about this compound. Understanding the evidence base — especially the distinction between preclinical animal data and established human clinical evidence — is essential for providing accurate, responsible, and professionally credible client education.
A: Rodent studies from the Zagreb research group have shown BPC-157 to be biologically active when administered orally, which is unusual for a peptide. However, human oral bioavailability data from clinical pharmacokinetic studies has not been published as of 2025. Human and rodent gastrointestinal physiology differ in ways that could affect peptide bioavailability, so oral bioavailability in rodents should not be assumed to translate directly to humans without human pharmacokinetic confirmation.
A: Vietnam Peptides supplies research-grade BPC-157 (including a BPC-157 + TB-500 20mg research stack) for scientific investigators. Products are supplied strictly for research purposes and are not for human therapeutic use. Researchers should review local regulatory requirements before procurement.
Related Articles
- Vietnam Peptides Knowledge Hub — comprehensive research guides covering BPC-157, TB-500, recovery peptides and more
- Peptide FAQ: Research, Storage and Usage
- Browse Recovery Research Peptides
Related Research Products
Combination of two leading tissue repair research peptides in a single research-grade product. Suitable for connective tissue, muscle, and gastrointestinal healing research.
View Product →Research-grade Thymosin Beta-4 analogue for tissue repair, recovery, and connective tissue healing investigations.
View Product →Related Research Plans
For health coaches and wellness professionals guiding clients through recovery-focused research, the Vietnam Peptides Recovery Plan provides a structured framework for understanding compound selection and protocol design in tissue repair research contexts.
Explore the Recovery Plan →Scientific References
- Sikiric P, Seiwerth S, Rucman R, et al. (2013). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 19(1):126–32. DOI: 10.2174/092986712803413961
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 110(3):774–80. DOI: 10.1152/japplphysiol.00945.2010
- Sikiric P, Seiwerth S, Rucman R, et al. (2018). Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 16(10):1465–1489. DOI: 10.2174/1570159X16666180302153305
- Huang T, Zhang K, Sun L, et al. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 9:2485–99. DOI: 10.2147/DDDT.S82030
- Sikiric P, Seiwerth S, Brcic L, et al. (2006). Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 12(23):2875–2890. DOI: 10.2174/138161206777947552
- Tudor M, Jandric I, Marovic A, et al. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept. 160(1–3):26–32. DOI: 10.1016/j.regpep.2009.11.012
- Sikiric P, Jelovac N, Jelovac-Gjeldum A, et al. (2000). Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behaviour disturbances. Eur Neuropsychopharmacol. 10(3):163–70. DOI: 10.1016/s0924-977x(00)00063-9
- Gwyer D, Bhatt N, Hall JE. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in healing. Vet Med Sci. 5(3):273–280. DOI: 10.1002/vms3.174
Conclusion
BPC-157 is one of the most comprehensively studied research peptides in the preclinical literature, with a research profile spanning over 30 years and 100+ published studies documenting effects across gut, muscle, tendon, ligament, bone, and nervous system tissue in rodent models. Its multi-tissue healing potential, multi-mechanism action, and unusual stability in biological environments make it a compound of genuine scientific interest.
For health coaches and wellness professionals, understanding BPC-157 means being able to accurately represent its evidence base — explaining what has been shown in animal studies while clearly communicating the absence of large-scale human clinical trials that would confirm these findings in humans. This balanced, evidence-informed approach is both professionally responsible and provides genuine value to clients navigating the complex landscape of peptide research.
Explore BPC-157 research products at Vietnam Peptides via our Products Page and access additional educational resources through the Knowledge Hub.
Primary Entity: BPC-157 (Body Protection Compound 157)
Related Entities: Predrag Sikiric (University of Zagreb), TB-500 (Thymosin Beta-4 analogue), VEGFR2, Nitric Oxide Synthase, Angiogenesis, Fibroblasts, Satellite Cells, Collagen, Gastric Juice BPC Protein, NSAID-induced gut damage, Actin polymerisation
Search Intent: Informational — What is BPC-157, how does it work, what does research show
Key Questions Answered: What is BPC-157? How does BPC-157 work? What tissues does BPC-157 affect? Is BPC-157 safe? Is BPC-157 the same as TB-500? Has BPC-157 been tested in humans? Can BPC-157 be taken orally?
Evidence Sources: Sikiric et al. (multiple, University of Zagreb), Chang et al. 2011 (J Appl Physiol), Huang et al. 2015 (Drug Des Devel Ther), Gwyer et al. 2019 (Vet Med Sci), Tudor et al. 2010
Relevant User Profiles: Health Coaches, Wellness Professionals, Functional Medicine Practitioners, Athletes, Sports Medicine Researchers, Biohackers, Recovery Users
Knowledge Graph Connections: BPC-157 → Body Protection Compound → Gastric Juice → Tissue Repair → VEGFR2 → Angiogenesis → Tendon Healing → Gut Health → Neuroprotection → Recovery Research Peptides Vietnam